<DOC>
	<DOCNO>NCT02267863</DOCNO>
	<brief_summary>This phase 1b study determine maximum tolerate dose ( MTD ) , dose limit toxicity ( DLT ) recommend phase 2 dose APTO-253 HCl patient relapse refractory hematologic malignancy .</brief_summary>
	<brief_title>A Study APTO-253 HCl Patients With Relapsed Refractory Hematologic Malignancies</brief_title>
	<detailed_description>This open label , phase 1b dose escalation two disease specific expansion , multicenter , safety , pharmacokinetic pharmacodynamic study determine maximum tolerate dose ( MTD ) appropriate dose MTD reach identify recommended phase 2 dose APTO-253 HCl patient relapse refractory hematologic malignancy .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Male female 18 year age old Histologically cytologically proven diagnosis hematologic malignancy standard therapy option fail Meet laboratory parameter requirement study entry Pregnancy breast feed History prior malignancy Autoimmune hemolytic anemia Acute Promyelocytic Leukemia Uncontrolled clinically significant diseaserelated metabolic disorder Other serious illness medical condition Patients exhibit allergic reaction compound structurally similar APTO253 HCl</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>